

Powered by the Sharekhan 3R Research Philosophy



What has changed in 3R MATRIX Old New RS ↔ RQ ↔ RV ↔


Company details

Market cap:	Rs. 3,827 cr
52-week high/low:	Rs. 295/191
NSE volume: (No of shares)	8.7 lakh
BSE code:	500730
NSE code:	NOCIL
Free float: (No of shares)	11.0 cr

Shareholding (%)

Promoters	33.8
FII	4.5
DII	5.1
Others	56.6

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	-12.4	-14.5	-2.2	-11.5
Relative to Sensex	-17.7	-18.3	-14.4	-12.6

Sharekhan Research, Bloomberg

NOCIL Ltd

Weak show; demand concerns temporary

Specialty Chemical	S	Sharekhan code: NOCIL		
Reco/View: Buy	\leftrightarrow	CMP: Rs. 230	Price Target: Rs. 305	\downarrow
↑ (Jpgrade	→ Maintain ↓	Downgrade	

Summary

- Q2FY23 performance was subdued with a miss of 19%/37%/45% in revenue/operating profit/PAT at Rs. 389 crore/Rs. 62 crore/Rs. 36 crore, down 24%/40%/46% q-o-q. The large miss was due to sharply lower-than-expected volume (down 23% q-o-q) and higher per unit opex on lower utilisation and elevated energy cost.
- Steep volume decline of 13%/23% y-o-y/q-o-q to 11,817 tonnes was on the account of lower export volumes given a recessionary trend in key markets while domestic volume witnessed some improvement. Despite beat in per unit gross margin, EBITDA margin of Rs. 52/kg (down 22% q-o-q) missed our estimate as beat in realisation was more than offset by higher per unit opex on volume decline.
- Management expects near-term export demand to remain under pressure given recessionary trend and its
 difficult to guide on timeline to achieve optimum utilisation. Having said that, NOCIL is confident on long-term
 growth, aspires to improve market share and sees growth from Europe plus one opportunity. We have lowered
 our FY23-24 earnings estimate to factor lower volume/margin assumption.
- We maintain a Buy on NOCIL but lower the PT to Rs. 305 to reflect earnings cut. Our expectation of earnings recovery over FY24E-25E, potential gain in global market share (benefit of China/Europe plus One strategy) makes valuation attractive at 16.5x/14.3x FY24E/FY25E EPS.

Q2FY23 results were weak with a sharp miss on all fronts primarily due to lower-than-expected sales volume and EBITDA margin. Consolidated revenue of Rs. 389 crore (up 3.8% y-o-y; down 23.5% q-o-q) was 19% below our estimates of Rs. 486 crore due to a sharp miss of 27% in sales volumes at 11,817 tonnes (down 13%/23% y-o-y/q-o-q) partially offset by better-than-expected blended realisation at Rs. 329/kg (down only 1% q-o-q and versus estimate of Rs. 300/kg). EBITDA margin of Rs. 52/kg (up 42% y-o-y; down 22% q-o-q) was significantly below our estimate of Rs. 62/kg primarily on the account of sharply higher-than-expected per unit opex (up 17% q-o-q) as steep volume de-growth impacted operating leverage. On the positive side, gross margin remained resilient at Rs. 155/kg (flat q-o-q) and was 9% above our estimate of Rs. 142/kg. Consequently, operating profit/PAT of Rs. 62 crore/Rs. 36 crore, down 40%/46% q-o-q was and 37%/45% below our estimate due to weak volume, pressure in per unit opex and higher tax rate of 26.4% (versus assumption of 25%).

Key positives

- Gross margin remained resilient at Rs. 155/kg, flat q-o-q.
- Domestic market has seen volume growth in Q2FY23.

Keu negatives

- Sharply lower-than-expected sales volume of 11,817 tonnes; down 23% q-o-q due to steep decline in export volume.
- Miss of 15% in EBITDA margin at Rs. 52/kg, down 22% q-o-q.
- Muted demand outlook in near term due to recessionary environment.

Management Commentary

- Management hinted that near term export demand to remain muted given global recessionary environment and destocking but do not see any structural change in long growth outlook. Europe accounts for 10-15% of global rubber production and current challenges environment provides growth opportunity.
- Raw material price remained flat q-o-q but continues to remain volatile and demand slowdown in China could result in dumping of rubber chemical and this could affect rubber chemical prices for the next 1-2 quarters.
- Q2FY23 utilisation at 65-70% versus 70% in Q1FY23 and management indicated that the current uncertain demand
 environment makes it difficult to predict timeline of optimum plant utilisation (in the past quarter management
 guided for 3-6 months delay from original guidance of Sep'23 to reach optimum plant utilisation on expanded
 capacity of 110,000 tonnes).
- Debottlenecking is on track to be completed in next 12 months and would be sufficient meet demand for next 1-2 years. New capex plan under evaluation and would take decision at an appropriate time.
- Other updates 1) Europe accounts for 20% of total export volumes, 2) maintained market share at last year level, 3) domestic realisations are 10% higher than export realisation.

Revision in estimates — We have lower our FY23 and FY24 earnings estimate to factor volume and margin assumption. We have also introduced our FY25 earnings estimate in this report.

Our Call

Valuation – Maintain Buy with revised PT of Rs. 305: Although FY23 volume growth outlook is subdued but long-term structural growth outlook remains intact supported by growth in tyre industry and Europe plus one opportunity. A potential volume recovery and resilient margin would drive earnings recovery. We believe that NOCIL is a play on import substitution and China/Europe Plus One strategy by global customers and the same would drive market share gains going forward. Valuation of 16.5x/14.3x FY24E/FY25E EPS is attractive considering our expectation of sharp PAT recovery (post subdued FY23) over FY24E-25E and improvement in RoE to 14-15% (versus 12.9% in FY22). Hence, we maintain a Buy on NOCIL with a revised PT of Rs. 305 (lowered to reflect cut in earnings estimate).

Keu Risks

Slowdown in auto/tyre industry and delay in ramp-up of new capacity could impact volume growth. Competition from Chinese players could affect pricing and margins.

Valuation (Consolidated)				Rs cr
Particulars	FY22	FY23E	FY24E	FY25E
Revenue	1,571	1,841	2,181	2,475
OPM (%)	18.2	16.0	16.5	16.5
Adjusted PAT	176	182	232	268
% YoY growth	99.2	3.4	27.2	15.6
Adjusted EPS (Rs.)	10.6	10.9	13.9	16.1
P/E (x)	21.7	21.0	16.5	14.3
EV/EBITDA (x)	13.3	12.5	10.4	9.0
RoNW (%)	12.9	12.1	14.2	15.0
RoCE (%)	16.0	14.3	16.5	17.5

Source: Company; Sharekhan estimates



Big miss in Q2FY23 earnings as volume/margin disappoints

Q2FY23 consolidated revenue of Rs. 389 crore (up 3.8% y-o-y; down 23.5% q-o-q) was 19% below our estimates of Rs. 486 crore due to a sharp miss of 27% in sales volume at 11,817 tonnes (down 13%/23% y-o-y/q-o-q) partially offset by better-than-expected blended realisation at Rs. 329/kg (down only 1% q-o-q and versus an estimate of Rs. 300/kg). EBITDA margins of Rs. 52/kg (up 42% y-o-y; down 22% q-o-q) was significantly below our estimate of Rs. 62/kg primarily led by sharply higher-than-expected per unit opex (up 17% q-o-q) as steep volume de-growth impacted operating leverage. On the positive side, gross margins remained resilient at Rs. 155/kg (flat q-o-q) and was 9% above our estimate of Rs. 142/kg. Consequently, operating profit/PAT of Rs. 62 crore/Rs. 36 crore, down 40%/46% q-o-q was and 37%/45% below our estimate due to weak volume, pressure in per unit opex and higher tax rate of 26.4% (versus assumption of 25%).

Results (Consolidated)					Rs cr
Particulars	Q2FY23	Q2FY22	YoY (%)	Q1FY23	QoQ (%)
Revenue	389	375	3.8	509	-23.5
Total Expenditure	327	325	0.7	406	-19.5
Operating profit	62	50	23.3	103	-39.6
Other Income	1	1	-37.2	1	-18.1
Interest	0	0	21.7	0	0.0
Depreciation	14	11	30.6	14	1.9
Reported PBT	49	41	19.4	90	-45.8
Tax	13	11	19.0	23	-44.7
Reported PAT	36	30	19.5	66	-46.2
Equity Cap (cr)	17	17		17	
Reported EPS (Rs.)	2.1	1.8	19.2	4.0	-46.2
Margins (%)			BPS		BPS
OPM	15.9	13.4	252.7	20.2	-423.2
NPM	9.2	8.0	121.2	13.1	-386.8
Tax rate	26.4	26.5	-8.2	25.9	53.4

Source: Company; Sharekhan Research

Key operating metrics

Particulars	Q2FY23	Q2FY22	YoY (%)	Q1FY23	QoQ (%)
Volume (tonnes)	11,817	13,635	-13.3%	15,251	-22.5%
Realisation (Rs. /kg)	329	275	19.7%	334	-1.3%
RM cost (Rs. /kg)	174	164	6.4%	179	-2.6%
Gross margin (Rs. /kg)	155	112	39.3%	155	0.2%
EBITDA margin (Rs. /kg)	52	37	42.3%	67	-22.0%

Source: Company; Sharekhan Research

Outlook and Valuation

■ Sector View – Import substitution and export opportunities bode well for domestic rubber chemical players


Global rubber consumption stands at ~30 million tonnes annually and of this, rubber chemical has a ~3.5% share and is dominated by China, which accounts for ~75% of global rubber chemical production. Global customers are shifting sourcing of rubber chemicals from China to India and the same provides strong export growth opportunities for domestic players like NOCIL. Additionally, domestic demand for rubber chemicals is also set to stay strong, supported by restriction on tyre imports, improvement tyre demand from both OEM and replacement market and capex by tyre companies to expand capacity. Moreover, a potential antidumping duty on major rubber chemicals would result in import substitution and drive-up domestic players' volumes.

■ Company Outlook – Near volume to remain subdued, structural growth drivers intact

NOCIL has recently doubled its production capacity to 110,000 tonnes in time for a rubber chemical demand recovery cycle both in domestic and export markets. However, a recessionary environment in its key export market makes us cautious on H2FY23 volume growth. We have therefore lowered our volume growth estimate and now expect volume to witness 15% CAGR over FY22-25E. Resilient margin of >Rs. 50/kg and likely volume recovery would drive 15% PAT over FY22-25E.

■ Valuation – Maintain Buy on NOCIL with a revised PT of Rs. 305

Although FY23 volume growth outlook is subdued but long-term structural growth outlook remains intact supported by growth in tyre industry and Europe plus one opportunity. A potential volume recovery and resilient margin would drive earnings recovery. We believe that NOCIL is a play on import substitution and China/Europe Plus One strategy by global customers and the same would drive market share gains going forward. Valuation of 16.5x/14.3x FY24E/FY25E EPS is attractive considering our expectation of sharp PAT recovery (post subdued FY23) over FY24E-25E and improvement in RoE to 14-15% (versus 12.9% in FY22). Hence, we maintain a Buy on NOCIL with a revised PT of Rs. 305 (lowered to reflect cut in earnings estimate).



Source: Sharekhan Research



About company

NOCIL, incorporated in 1975, is part of Arvind Mafatlal Group and is the largest rubber chemical manufacturer in India with production capacity of 110 ktpa and market share of ~42%/5% in domestic/global markets. The company has presence in over 40 countries with exports accounting for 36% of FY2022 revenues. The business segments include Accelerator, Anti-oxidant, Pre/Post vulcanization inhibitor/stabilizer and Zinc based applications.

Investment theme

NOCIL is the key beneficiary of China plus one strategy and import substitution in niche market of rubber chemicals. Recent doubling of capacity has made in third largest rubber chemical manufacturers in term of capacity and ramp-up of utilisation would drive sustainable double digit volume growth and help expand global market share to "8% over next 2-3 years as compared to 5% currently. Volume growth coupled with margin expansion would drive strong earnings growth and consistent FCF generation. Balance sheet remains strong with net cash position.

Key Risks

- Slowdown in auto/tyre industry and delay in ramp-up of new capacity could impact volume growth.
- Competition from Chinese players could impact pricing and margin.

Additional Data

Key management personnel

Mr. Hrishikesh Arvind Mafatlal	Chairman
Mr. S.R. Deo	Managing Director
P Srinivasan	Chief Financial Officer

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Tejas Trivedi	1.75
2	Trivedi Shivani Tejas	1.63
3	Canara Robeco Asset Management Co Ltd	1.52
4	Aagam Agencies Pvt Ltd	1.16
5	HN Safal Infra Space Pvt Ltd	1.10
6	IDFC Mutual Fund	1.04
7	Trivedi Minaxi Balchandra	0.99
8	Trivedi Khushi Tejas	0.99
9	Dimensional Fund Advisors LP	0.89
10	Deo Sudhir Ramchandra	0.48

Source: Bloomberg (Old data)

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research



by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com.

Registered Office: Sharekhan Limited, The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA, Tel: 022 - 67502000/ Fax: 022 - 24327343. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O/CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183.

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.